Tian Xie

Dr. Tian Xie


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
TXTian Xie
Tian Xie
WHWei He
Wei He
ZLZhihao Li
Zhihao Li
HDHao Dong
Hao Dong
XLXingyi Li
Xingyi Li
YZYifan Zheng
Yifan Zheng
Introduction: Metastatic dissemination is a major determinant of poor outcome in lung adenocarcinoma (LUAD). However, molecular features associated with distinct metastatic states, particularly lymph node and brain metastases, remain incompletely defined. We investigated the relationship between HAX1 and LUAD metastatic progression. Methods: We reanalyzed publicly available single-cell RNA-sequencing data from GSE131907 to characterize HAX1 expression and associated transcriptional programs across normal lung, primary LUAD, advanced tumors, metastatic lymph nodes (mLN), and brain metastases. Findings were validated using additional public datasets from GEO and TCGA, including the independent single-cell dataset GSE69405. Clinical LUAD specimens were analyzed to assess HAX1 protein expression and its clinicopathological associations. Functional validation was performed in A549 and H1975 cells, and tumor growth was assessed using an A549-derived subcutaneous xenograft model. Results: HAX1 expression and the proportion of HAX1-positive epithelial cells increased across LUAD disease states and were significantly enriched in mLN and brain-metastatic epithelial populations compared with primary tumors. In a 125-patient clinical cohort, high HAX1 expression was associated with lymph node metastasis, advanced stage, and shorter overall survival, and remained independently associated with lymph node metastasis after adjustment for T stage (OR = 2.581, 95% CI 1.161–5.742; P = 0.020). An independent single-cell dataset further confirmed elevated HAX1 expression in brain-metastatic LUAD cells. HAX1-associated transcriptional programs converged on E2F, MYC, MTORC1, DNA replication, and cell-cycle signatures, whereas brain-metastatic epithelial cells additionally exhibited mitochondrial and translational programs. Integrated analyses identified UBE2S, PITX1, GGH, and PDCD2L as HAX1-associated candidates.EPIC and TIMER analyses consistently showed inverse correlations between HAX1 expression and estimated B-cell, CD4+ T-cell, CD8+ T-cell, and macrophage abundance. HAX1 knockdown also reduced cell viability, increased the G0/G1-phase fraction and decreased the S-phase fraction, reduced G1/S-related protein levels and PI3K/AKT signaling, and inhibited subcutaneous xenograft growth. Conclusion: HAX1 is closely associated with metastatic progression of LUAD, with strong clinical evidence for lymph node involvement and reproducible enrichment in brain-metastatic epithelial cells. Its associations with cell-cycle programs and immune cell infiltration, together with its functional role in G1/S progression, support further investigation of HAX1 in metastatic adaptation and tumor–immune interactions.

14 August 2026 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
HDHao Dong
Hao Dong
YZYifan Zheng
Yifan Zheng
GWGaoming Wang
Gaoming Wang
XLXingyi Li
Xingyi Li
JLJing Luo
Jing Luo
YSYi Shen
Yi Shen
CDC73 is a canonical tumor suppressor; however, its biological functions in lung adenocarcinoma (LUAD) and the extracellular vesicle (EV)-mediated mechanisms through which it exerts its effects remain unclear. In this study, we systematically evaluated the diagnostic value, biological functions, and EV-mediated regulatory roles of CDC73 in LUAD. First, quantitative proteomic analysis was performed on plasma-derived EVs from six patients with early-stage LUAD and three healthy donors, followed by further validation of EV-borne CDC73 expression in plasma-derived EV samples from eight LUAD patients and eight healthy donors. We found that the level of EV-borne CDC73 protein (EV-CDC73) was significantly reduced in LUAD, indicating its potential value as a diagnostic liquid-biopsy biomarker. To define its functional role, we established LUAD cell lines stably overexpressing CDC73 (A549^OE and H1299^OE) and performed rescue experiments in combination with PTEN knockdown using siRNA. The tumor-suppressive effects of CDC73 were systematically assessed through experiments examining cell proliferation, cell-cycle progression, apoptosis, migration, and related molecular mechanisms. Meanwhile, EVs were isolated by ultracentrifugation from the conditioned media of A549, H1299, and human bronchial epithelial (HBE) cells to analyze the effects of EVs with different CDC73 levels on recipient A549 and HBE cells, and xenograft models were used for in vivo validation. The results showed that CDC73 overexpression markedly inhibited LUAD cell proliferation and migration, induced G1-phase arrest, and promoted apoptosis. Mechanistically, CDC73 exerted its tumor-suppressive effects by upregulating PTEN and inhibiting AKT activation, whereas PTEN knockdown partially reversed these effects. In vivo experiments further confirmed that CDC73 overexpression suppressed tumor growth and migration. In addition, EVs derived from LUAD cells with high CDC73 expression showed a reduced ability to induce malignant transformation-related phenotypes in HBE cells and suppressed the PTEN/AKT signaling axis; conversely, EVs derived from HBE cells with high CDC73 expression inhibited the malignant progression of LUAD cells. Collectively, CDC73 suppresses the malignant progression of LUAD through the PTEN/AKT signaling axis, while EV-borne CDC73 not only has potential diagnostic value but also directly regulates malignant phenotypes in recipient cells, highlighting its translational potential in the diagnosis and treatment of LUAD.